ANI Pharmaceuticals (NASDAQ:ANIP) Cut to Sell at StockNews.com

StockNews.com lowered shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a hold rating to a sell rating in a research report released on Tuesday morning.

A number of other research analysts have also issued reports on ANIP. Jefferies Financial Group started coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 14th. They set a “buy” rating and a $80.00 target price on the stock. JPMorgan Chase & Co. began coverage on ANI Pharmaceuticals in a research report on Wednesday, March 12th. They set an “overweight” rating and a $85.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, March 17th. Guggenheim upped their target price on ANI Pharmaceuticals from $84.00 to $86.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. Finally, Leerink Partners assumed coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price target on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $79.75.

ANI Pharmaceuticals Trading Down 1.3 %

ANIP stock opened at $65.12 on Tuesday. ANI Pharmaceuticals has a 52 week low of $52.50 and a 52 week high of $70.00. The company has a market capitalization of $1.42 billion, a PE ratio of -118.40 and a beta of 0.49. The company’s 50-day simple moving average is $62.15 and its 200 day simple moving average is $59.00. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74.

Insider Buying and Selling

In other news, SVP Krista Davis sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $60.86, for a total value of $60,860.00. Following the sale, the senior vice president now directly owns 66,525 shares in the company, valued at approximately $4,048,711.50. This trade represents a 1.48 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Meredith Cook sold 400 shares of the company’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total transaction of $25,332.00. Following the transaction, the vice president now owns 80,545 shares of the company’s stock, valued at approximately $5,100,914.85. This represents a 0.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 3,200 shares of company stock worth $191,776 in the last ninety days. 12.70% of the stock is owned by insiders.

Institutional Trading of ANI Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. US Bancorp DE lifted its stake in shares of ANI Pharmaceuticals by 842.9% in the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock valued at $33,000 after acquiring an additional 531 shares during the last quarter. KBC Group NV increased its holdings in ANI Pharmaceuticals by 89.2% in the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock worth $70,000 after purchasing an additional 600 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in ANI Pharmaceuticals in the fourth quarter valued at about $166,000. Rafferty Asset Management LLC acquired a new stake in shares of ANI Pharmaceuticals during the fourth quarter valued at about $200,000. Finally, Bridgefront Capital LLC bought a new stake in shares of ANI Pharmaceuticals during the fourth quarter worth about $204,000. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.